Cytori Therapeutics (NSDQ:CYTX) said this week that it bought San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs in a stock deal. Azaya shareholders will receive $2 million in CTYX stock. San Diego-based Cytori will also pay $2 million upfront for costs associated with Azaya’s new manufacturing facility in San Antonio. Cytori will acquire a […]
Featured
Patent board invalidates RainDance patent for obviousness
The Patent Trial and Appeal Board invalidated a RainDance Technologies patent earlier this week for obviousness. The patent, which covers a method for manipulating the size of liquid droplets used in microfluidic diagnostic tests, was challenged by manufacturer 10X Genomics Inc. The panel, after conducting an inter partes review, found that the technique’s characteristics, which […]
Researchers develop responsive, insulin-releasing skin patch
Researchers from the University of North Carolina at Chapel Hill, North Carolina State University and Changchun Institute of Applied Chemistry at the Chinese Academy of Sciences have developed a skin patch that measures blood glucose levels and releases insulin when levels climb too high. The team’s work testing the patch in mice was published earlier this month […]
Sanofi’s Suliqua combination therapy approved in European Union
Sanofi (NYSE:SNY) said today that the European Commission granted marketing authorization in Europe for its Suliqua combination product for adults with type II diabetes. The therapy is a fixed-ratio combination of basal insulin glargine and lixisenatide, intended to be used with metformin to improve patients’ glycemic control. Suliqua will be available in 2 pre-filled SoloSTAR pens at […]
Braeburn sets terms for $150m IPO
Braeburn Pharmaceuticals said today that it plans to raise $150 million by offering 7,692,308 shares of its common stock. The Princeton, N.J.-based company wrote in regulatory filings that it expects the initial public offering price for its stock to be between $18.00 and $21.00 apiece. Apple Tree Partners has indicated an interest in buying $50 million of shares […]
Allergan pays $15m for failing to disclose Actavis ‘white knight’ offer
The SEC said yesterday that Allergan (NYSE:AGN) will pay a $15 million fine for failing to disclose its 2014 merger talks with Actavis. In June 2014, Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) offered a tender bid for the Irvine, Calif.-based company which was followed by a 7 month-long hostile pursuit by Valeant and co-bidder Pershing Square Capital Management. In November […]
Pulmatrix shares soar after winning FDA designation
Pulmatrix (NSDQ:PULM) shares were up 159% to $1.79 apiece in mid-afternoon trading today after the company announced that its drug candidate for treating fungal infections in the lungs of cystic fibrosis patients was designated as a ‘qualified infectious disease product’ by the FDA. With the designation, the Lexington, Mass.-based company will receive 5 years of […]
leon-nanodrugs, Bionpharma to develop microjet reactor-based dermatological product
leon-nanodrugs GmbH and Bionpharma Inc. said yesterday that the 2 groups inked a deal to develop a dermatological product using leon-nanodrugs’ microjet reactor nanotechnology platform. The companies will share the development of the undisclosed product. Development will be done at leon-nanodrugs’ U.S.-based formulation partner CoreRx in Clearwater, Florida. Bionpharma will market and distribute the product […]
Bio-Rad Laboratories to acquire RainDance Technologies
Bio-Rad Laboratories (NYSE:BIO) said yesterday that it inked a definitive agreement to acquire RainDance Technologies for an undisclosed amount. The Hercules, Calif.-based company said it expects the transaction to close in the 1st quarter of 2017 and that it will reveal the terms of the acquisition when it discusses its 4th quarter and full-year financial […]
Nordisk takes a hit from Trump, lawsuit
Novo Nordisk (NYSE:NVO) shares fell more than 5% yesterday, following a lawsuit alleging that the Danish diabetes giant made misleading earning forecasts and comments from the President-elect regarding drug prices. The securities class action lawsuit against Nordisk also named Eli Lilly (NYSE:LLY), Sanofi (NYSE:SNY) and Merck (NYSE:MRK), claiming that Nordisk’s reported earnings and forecasts were inflated through price fixing for the company’s […]